HEIDELBERG, Germany & HYDERABAD, India--(BUSINESS WIRE)--SYGNIS Pharma AG (Frankfurt:LIO; ISIN DE0005043509; Prime Standard) and the leading Indian pharmaceutical company Dr. Reddy’s Laboratories (NYSE:RDY) today announced the signing of an exclusive 10 year agreement for the supply of the active ingredient AX200, a biological molecule in development by SYGNIS for the treatment of Stroke and other neurodegenerative disorders. The Agreement secures the supply of AX200 far beyond the clinical development and provides a solid basis for the envisaged marketing of the compound.
